This page contains published papers relating to paediatric oncology in low and middle income countries. Click here for published papers that have authors from the SIOP PODC Nutrition Group.
- New Late Effects Surveillance System (LESS) Study Scan Vol 2 Spring 2021
- Late Effects Surveillance System (LESS) Study Scan Vol 1 Winter 2021
- Equity in global health research in the new millennium: trends in first-authorship
- Treating Childhood Cancer in Sub-Saharan Africa factsheet
- The Challenges of Delivering Cost-Effective and Affordable Care to Children With Cancer in the Developing World
- The Cost-Effectiveness of Treating Childhood Cancer in 4 Centers Across Sub-Saharan Africa
- Treatment of childhood Hodgkin lymphoma in sub-Saharan Africa: A report from the French-African Paediatric Oncology Group (GFAOP)
- Health system determinants of access to essential medicines for children with cancer in Ghana
- Pediatric Oncology Clinical Trials and Collaborative Research in Africa: Current Landscape and Future Perspectives
- Working Together to Build a Better Future for Children With Cancer in Africa
- Baseline status of paediatric oncology in ten low-income or mid-income countries receiving My Child Matters support: a descriptive study
- Barriers to effective treatment of pediatric solid tumors in middle-income countries: Can we make sense of the spectrum of non-biological factors that influence outcomes?
- Funding paediatric surgery procedures in sub-Saharan Africa
- Collecting Data in the Age of COVID-19: Will persons with disabilities be left out?
- The global burden of childhood and adolescent cancer in 2017: an analysis of the Global Burden of Disease Study 2017
- Sustainable care for children with cancer
- Sustainable care for children with cancer: a Lancet Oncology Commission
- Estimating the total incidence of global childhood cancer: a simulation-based analysis
We want to welcome you to read this new publication released by the Late Effects Surveillance System study group. Even though the world faces hard times during the last months we can’t ignore still existing problems beside coronavirus. One of these issues are late effects after childhood cancer. Numbers of publications in this field have increased from year to year. That’s why we decided to publish this newsletter from now on as quarterly magazine. It contains abstracts from current publications about late effects after childhood cancer. Those who want
to read more details, can use links on the same page to get to full text page. We think to provide all professions who are involved in care of childhood cancer patients (the future survivors), childhood cancer survivors, and everyone who is interested in this subject with this magazine an helpful tool.
Authors: Christian Müller, Prof. Dr. med. Thorsten Langer et al
More LESS publications here.
Equity in global health research in the new millennium: trends in first-authorship for randomized controlled trials among low- and middle-income country researchers 1990-2013
Developing the research capacity of low- and middle-income countries (LMICs) has been shown to be one of the key ways that international health programmes and health research can create sustained benefit in these countries.
Authors: Margaret Kelaheret al
Treating Childhood Cancer in Sub-Saharan Africa can be very cost-effective. Factsheet produced by Policy and Economics Research in Childhood Cancer (PERCC) and The Hospital for Sick Children (SickKids), Toronto, Canada
The Challenges of Delivering Cost-Effective and Affordable Care to Children With Cancer in the Developing World
The authors of this report are a cohesive amalgam of experts in the relevant methods and local practitioners with the requisite experience and expertise. Indeed, the senior authors have been in the vanguard of efforts to determine the cost-effectiveness of pediatric cancer care in low- and middle-income countries (LMICs). In this study, the numerous assumptions, estimates, extrapolations, and allocations are realistic necessities in the absence of relevant information, which is so common in LMICs, and have been well defended methodologically (as with multiple sensitivity analyses).
Authors: Ronald D. Barr et al
Background: The treatment of childhood cancer often is assumed to be costly in African settings, thereby limiting advocacy and
policy efforts. The authors determined the cost and cost-effectiveness of maintaining childhood cancer centers across 4 hospitals
throughout sub-Saharan Africa.
Authors: Jessie Githang’a et al
Treatment of childhood Hodgkin lymphoma in sub-Saharan Africa: A report from the French-African Paediatric Oncology Group (GFAOP)
Background: Childhood Hodgkin lymphoma (HL) is typically treated by chemo- and radiotherapy, depending on the stage of the disease. Studies on the treatment of HL by chemotherapy alone have shown encouraging results.
Objective: To evaluate the feasibility, epidemiological and therapeutic aspects of paediatric HL treated with only COPP/ABV hybrid chemotherapy (cyclophosphamide, vincristine, procarbazine, prednisone, adriamycin, bleomycin and vinblastine).
Authors: F Traore et al
Evidence of the context-specific challenges related to childhood cancer drug (CCD) access is vital to improving outcomes for children with cancer in low- and middle-income countries, such as Ghana. We sought to determine the availability and cost of essential CCD in Ghana and identify the underlying determinants of access.
Authors: Rhonda Boateng et al
In sub-Saharan Africa, there is a growing awareness of the burden of paediatric surgical diseases. This has highlighted the large discrepancy between the capacity to treat and the ability to afford treatment, and the effect of this problem on access to care. This review focuses on the sources and challenges of funding paediatric surgical procedures in sub-Saharan Africa.
Authors: Sebastian O. Ekenze
Pediatric Oncology Clinical Trials and Collaborative Research in Africa: Current Landscape and Future Perspectives
Adequate clinical services have yet to be established in the majority of African countries, where childhood cancer survival rates vary from 8.1% to 30.3%. The aim of this review is to describe the landscape of pediatric oncology trials in Africa, identify challenges, and offer future opportunities for research collaborations.
Authors: Jaques van Heerden et al
Read this paper to see how centres participating in CANCaReAfrica & SIOP, SIOP Africa, World Health Organization Global Initiative for Childhood Cancer (WHOGICC) & other partners are working together to build a better future for children with cancer in Africa.
Authors: Inam Chitsike et al
Baseline status of paediatric oncology in ten low-income or midincome countries receiving My Child Matters support: a descriptive study
Paediatric oncology has improved substantially in some comparatively low-income countries, and therefore, might be improved in other countries as well. Successful initiatives have improved access to treatment in countries in central and south America, Africa, and Asia. Collectively, these initiatives are twinning partnerships that pair medical institutions in high-income countries with those in low-income and mid-income countries.
Authors: Raul C Ribeiro et al
Barriers to effective treatment of pediatric solid tumors in middle-income countries: Can we make sense of the spectrum of non-biological factors that influence outcomes?
Delivery of effective treatment for pediatric solid tumors poses a particular challenge to centers in middle-income countries (MIC) already vigorously addressing pediatric cancer. This study aimed to improve our understanding of barriers to effective treatment of pediatric solid tumors in MIC
Authors: Paola Friedrich et al
Children and adults with disabilities often face discrimination, leading to reduced access to basic social services and general lack of recognition. Addressing discrimination and promoting inclusion is an issue of concern in all sectors, and can be accomplished through quality data and evidence-based advocacy and policy.
Inclusive data are key to eliminating discrimination on the basis of disability and to accelerating global efforts towards inclusive programming. The production of inclusive data demands the involvement of persons with disabilities in all data collection processes and outcomes. This will help ensure that their experiences and needs are adequately reflected in the evidence being generated.
The global burden of childhood and adolescent cancer in 2017: an analysis of the Global Burden of Disease Study 2017
Accurate childhood cancer burden data are crucial for resource planning and health policy prioritisation. Model-based estimates are necessary because cancer surveillance data are scarce or non-existent in many countries. Although global incidence and mortality estimates are available, there are no previous analyses of the global burden of childhood cancer represented in disability-adjusted life-years (DALYs).
Authors: Lisa M Force et al
Commissions from the Lancet journals – a collection of papers
Cancer kills more than 100,000 children each year, and yet 80% of paediatric cancers are curable with currently available interventions. Notably, the majority of these deaths occur in low‐income and middle-income countries where children have poor access to health services. It is crucial that as countries transition to universal health care, childhood cancers are recognised as a priority for inclusion in benefits packages. Yet no reliable data are available in low-income and middle-income countries on the current and future burden of childhood cancer; on cost of effective interventions; on current coverage levels for diagnostic, treatment, and care services; or on the cost, feasibility, or health and economic benefits of scaling-up effective coverage.
We estimate that there will be 13·7 million new cases of childhood cancer globally between 2020 and 2050. At current levels of health system performance (including access and referral), 6·1 million (44·9%) of these children will be undiagnosed. Between 2020 and 2050, 11·1 million children will die from cancer if no additional investments are made to improve access to health-care services or childhood cancer treatment. Of this total, 9·3 million children (84·1%) will be in low-income and lower-middle-income countries. This burden could be vastly reduced with new funding to scale up cost-effective interventions.
Lancet Oncol 2020; 21: e185–224
Authors: Rifat Atun et al
We developed a microsimulation model to simulate childhood cancer incidence for 200 countries and territories worldwide, taking into account trends in population growth and urbanicity, geographical variation in cancer incidence, and health system barriers to access and referral that contribute to underdiagnosis.
Lancet Oncol. 2019 Apr;20(4):483-493. doi: 10.1016/S1470-2045(18)30909-4. Epub 2019 Feb 26
Authors: Zachary J Ward et al